Nanotechnology and Its Potential Implications in Ovary Cancer

2021 ◽  
pp. 161-175
Author(s):  
Bimal Prasad Jit ◽  
Biswajita Padhan ◽  
Ashok Sharma
Keyword(s):  
Ovary Cancer

scholarly journals Evaluating the Association between p53 Codon 72 Arg>Pro Polymorphism and Risk of Ovary Cancer: A Meta-Analysis

PLoS ONE ◽  
2014 ◽  
Vol 9 (4) ◽  
pp. e94874 ◽  
Author(s):  
Mohammed A. A. Alqumber ◽  
Naseem Akhter ◽  
Shafiul Haque ◽  
Aditya K. Panda ◽  
Raju K. Mandal
Keyword(s):  
Meta Analysis ◽  
P53 Codon 72 ◽  
Codon 72 ◽  
Ovary Cancer

scholarly journals HMGB1 Protein Interactions in Prostate and Ovary Cancer Models Reveal Links to RNA Processing and Ribosome Biogenesis through NuRD, THOC and Septin Complexes

Cancers ◽  
2021 ◽  
Vol 13 (18) ◽  
pp. 4686
Author(s):  
Aida Barreiro-Alonso ◽  
Mónica Lamas-Maceiras ◽  
Lidia Lorenzo-Catoira ◽  
Mercedes Pardo ◽  
Lu Yu ◽  
...  
Keyword(s):  
Cancer Progression ◽  
Protein Interactions ◽  
Rna Processing ◽  
Ribosome Biogenesis ◽  
Affinity Purification ◽  
Regulation Of Transcription ◽  
Nurd Complex ◽  
Hmgb1 Protein ◽  
Ovary Cancer ◽  
Public Data

This study reports the HMGB1 interactomes in prostate and ovary cancer cells lines. Affinity purification coupled to mass spectrometry confirmed that the HMGB1 nuclear interactome is involved in HMGB1 known functions such as maintenance of chromatin stability and regulation of transcription, and also in not as yet reported processes such as mRNA and rRNA processing. We have identified an interaction between HMGB1 and the NuRD complex and validated this by yeast-two-hybrid, confirming that the RBBP7 subunit directly interacts with HMGB1. In addition, we describe for the first time an interaction between two HMGB1 interacting complexes, the septin and THOC complexes, as well as an interaction of these two complexes with Rab11. Analysis of Pan-Cancer Atlas public data indicated that several genes encoding HMGB1-interacting proteins identified in this study are dysregulated in tumours from patients diagnosed with ovary and prostate carcinomas. In PC-3 cells, silencing of HMGB1 leads to downregulation of the expression of key regulators of ribosome biogenesis and RNA processing, namely BOP1, RSS1, UBF1, KRR1 and LYAR. Upregulation of these genes in prostate adenocarcinomas is correlated with worse prognosis, reinforcing their functional significance in cancer progression.

scholarly journals Post-menopausal ovary cancer is enriched of Ddx4+ primordial oogones as putative cancer stem cells

2016 ◽  
Vol 27 ◽  
pp. iv78
Author(s):  
E. Silvestris ◽  
P. Cafforio ◽  
S. D'Oronzo ◽  
C. Felici ◽  
G. Loverro ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Ovary Cancer ◽  
Post Menopausal

scholarly journals Tumor microenvironment in high serous ovary cancer: Characterization of the infiltration pattern and analysis of its prognostic value

2017 ◽  
Vol 28 ◽  
pp. v338
Author(s):  
F. Herrera Cañizares ◽  
A. Chipirliu ◽  
C. Caballero ◽  
A. Herreros Pomares ◽  
S. Calabuig Fariñas ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Prognostic Value ◽  
Ovary Cancer

Interleukine 10 -592 c/a and interleukine 8 -251 t/a polymorphisms in ovary cancer: New prognostic biomarkers?

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15532-e15532
Author(s):  
Ramon Andrade De Mello ◽  
Dania Sofia Marques ◽  
Joana Savva-Bordalo ◽  
Monica Gomes ◽  
Joana Assis ◽  
...  
Keyword(s):  
Clear Cell ◽  
Statistical Significance ◽  
Progression Free Survival ◽  
Prognostic Biomarkers ◽  
Confidential Interval ◽  
Free Survival ◽  
Ovary Cancer ◽  
Kaplan Meier ◽  
Pcr Rflp

e15532 Background: Interleukine (IL) 10 –592C/A and IL8 –251T/A polymorphisms previous showed an important role in cell proliferation, cell migration and angiogenesis. Therefore, we conduct a study in order to assess the role of those genetic polymorphisms as prognostic biomarkers in epithelial ovary cancer (EOC). Methods: Design: Retrospective study from 1996 to 2010. Setting: Histological confirmed EOC patients treated at our institution. Laboratory: Genotyping of IL10–592 C/A and IL8 -251T/A were performed by PCR-RFLP. DNA samples were obtained from patients’ peripheral blood. Statistical analysis: Logistic regression were used to calculate odds ratio (OR) and 95% confidential interval (95% CI). Overall survival (OS) and progression-free-survival (PFS) were performed using Kaplan-Meier analysis. Statistical significance was considered for p < 0.05. Results: It was recruited 156 participants. Median age was 53 (16 – 80) years-old. Genotype frequency distribution for IL8-251 were T/T (50%), T/A (50%) and for IL10–592, C/C (53.8%), C/A (39.7%), A/A (6.4%). These follow genotypes were associated with lymph node, pelvic and peritoneal relapse: IL10–592C/A (OR 0.229, 95% CI: 0.055 – 0.943, p = 0.041) and IL8–251T/A (OR 6.667, 95% CI: 1.359 – 32.701, p = 0.019). In overall, IL8–251T/A genotype had higher OS than IL8-251T/T genotype: 115 versus 95 months, p = 0.010. In clear cell tumors (CCT), IL8–251T/A genotype had less OS than IL8-251T/T genotype: 92 versus 107 months, p = 0.004. To IL10–592 genotypes, OS were 104 (A/A), 107 (C/A), 103 (C/C) months, p = 0.637, and PFS were 9 (A/A), 14 (C/A), 20 (C/C) months, p = 0.057. However, in CCT, PFS for IL10–592 genotypes were 4 (A/A), 56.73 (C/A), 20 (C/C) months, p = 0.023. Conclusions: Our results suggest that IL8–251T/A polymorphism could represent a prognostic biomarker in overall EOC. IL10–592C/A polymorphisms are associated with relapse and PFS mainly in CCT. Nevertheless, furthers prospective studies are warranted in order to assess its role in pharmacogenomics framework.

Sign in / Sign up

Export Citation Format

Share Document